Juan A Flores-Montero, MD^1,2*, Bruno Paiva, PhD^3*, Luzalba Sanoja-Flores, M.Sc.^1,2*, Noemi Puig, MD, PhD^4*, Omar García, PhD^1,5*, Sebastian Böttcher, MD, PD^6*, José J Pérez-Morán^1,5*, Maria Belen Vidriales, MD, PhD^1,5*, Maria-Victoria Mateos^1,5, Ramon Garcia-Sanz, MD PhD^1,7*, Cristina Jimenez, BsC^1,5*, Marcos González, MD, PhD^8*, Joaquin Martinez-López, MD.PhD^9*, María Consuelo Cañizo, MD, PhD^10*, Jesus San Miguel, MD PhD^3*, Brian Durie, MD¹¹, Jacques J.M. van Dongen¹² and Alberto Orfao, MD, PhD^1,2

¹Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Salamanca, Spain
²Servicio General de Citometría (NUCLEUS) and Department of Medicine, University of Salamanca, Salamanca, Spain
³Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
⁴Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
⁵Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
⁶Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany
⁷Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain
⁹Hematology, Hospital 12 de Octubre, Madrid, Spain
¹⁰Hematology, Salamanca Universitary Hospital, Salamanca, Spain
¹¹Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
¹²Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

Andrew Spencer¹, Sridurga Mithraprabhu, Post doc^1*, Malarmathy Ramachandran^1*, Daniela Klarica, RN^2*, Jay Hocking, MD^1*, Laura Mai^3*, Stephanie Walsh^3*, David Broemeling^3*, Andre Marziali^3*, Anna Kalff, MD¹, Matthew Wiggin^3*, Brian G. M. Durie, MD⁴ and Tiffany T. Khong, PhD¹

¹Myeloma Research Group, ACBD, Alfred Health-Monash University, Melbourne, Australia
²Malignant Haematology and Stem Cell Transplantation Service, Alfred Health, Melbourne, Australia
³Boreal Genomics, Vancouver, Canada
⁴Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA

Christoph Heuck, MD¹, Shweta S. Chavan, PhD^1*, Caleb K. Stein, MS^1*, Ruslana Tytarenko^1*, Niels Weinhold, PhD^1*, Siraj Ali, MD, PhD^2*, Vincent A. Miller, MD^2*, Sharmilan Thanendrarajan, MD¹, Carolina Schinke, MD^1*, Meera Mohan^1*, Jeffery Sawyer^3*, Erich Allen Peterson, PhD, BS, MS^1*, Michael Bauer^1*, Timothy C. Ashby^1*, Donald Johann, MD, MS¹, Frits van Rhee, MD, PhD¹, Sarah Waheed, MD^1*, Maurizio Zangari, MD⁴, Faith E Davies, MD¹, Bart Barlogie, MD, PhD¹ and Gareth J Morgan, MD PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Foundation Medicine, Inc., Cambridge, MA
³Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR
⁴Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR

Niccolo Bolli, mD, PhD^1,2*, Hervé Avet-Loiseau, MD^3*, Silvia Gimondi^2*, Yilong Li^1*, Vijitha Sathiaseelan^1*, Adam Samuel Sperling, MD, PhD⁴, Kenneth C Anderson, MD⁵, Stephane Minvielle^6*, Peter J Campbell, MD, PhD^7* and Nikhil C. Munshi, MD⁸

¹Wellcome Trust Sanger Institute, Cambridge, United Kingdom
²Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milan, Italy
³Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé, Toulouse, France
⁴Dana-Farber Cancer Institute, Boston, MA
⁵LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France
⁷Cancer genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
⁸Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA

Lorenzo Melchor, PhD^1,2*, John R Jones, MD^1,2*, Oleg Lenive^3*, Erich Allen Peterson, PhD, BS, MS^4*, Annamaria Brioli, MD, PhD^5,6*, Alex Murison, PhD^7,8*, Christopher P Wardell, PhD^8*, Martin F Kaiser^8*, Paula Proszek^8*, Eileen Mary Boyle, MD, PhD^8*, Dil B Begum^8*, Charlotte Pawlyn, MB BChir^1*, David C Johnson, PhD^8*, Inmaculada Rapado^9*, David A Cairns^10*, Walter M Gregory^10*, Roger G Owen¹¹, Graham H Jackson, MD, PhD¹², Mark T Drayson, MD, PhD^13*, Faith E Davies, MD^4,8, Joaquín Martínez-López, MD, PhD^14*, Richard S Houlston, MD PhD FRCP^15*, Mel Greaves, FRS², Brian A Walker, PhD⁸ and Gareth J Morgan, MD, PhD^1,4

¹The Institute of Cancer Research, London, United Kingdom
²Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
³Molecular and Population Genetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
⁴Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
⁵Seragnoli Institute of Hematology, Bologna University, School of Medicine, Bologna, Italy
⁶Institute of Cancer Research, London, United Kingdom
⁷University Health Network, The Princess Margaret Cancer Center, Toronto, Canada
⁸Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
⁹Hospital-12-de-Octubre, Madrid, Spain
¹⁰Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
¹¹St James's University Hospital, Haematological Malignancy Diagnostic Service, Leeds, United Kingdom
¹²Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
¹³Clinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom
¹⁴Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
¹⁵Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom

Christoph Heuck, MD¹, Niels Weinhold, PhD^1*, Erich Allen Peterson, PhD, BS, MS^1*, Michael Bauer^1*, Caleb K. Stein, MS^1*, Timothy Ashby^1*, Shweta S. Chavan, PhD^1*, Ruslana Tytarenko^1*, Owen W Stephens, PhD^1*, Tobias Meissner^2*, Donald Johann, MD, MS¹, Frits van Rhee, MD, PhD¹, Sarah Waheed, MD^1*, Sarah K. Johnson, PhD¹, Maurizio Zangari, MD¹, Aasiya Matin^1*, Nathan Petty, MS^1*, Shmuel Yaccoby, PhD¹, Faith E Davies, MD¹, Joshua Epstein, DSc¹, Bart Barlogie, MD, PhD¹ and Gareth J Morgan, MD PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
²Department of Molecular and Experimental Medicine, Avera Cancer Institute, La Jolla, CA